|
May 14
|
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
|
|
May 8
|
BioAtla to Participate in the Citizens JMP Life Sciences Conference
|
|
May 7
|
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
|
|
May 6
|
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
|
|
Apr 24
|
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Mar 28
|
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
|
|
Mar 27
|
BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
Q4 2023 Bioatla Inc Earnings Call
|
|
Mar 26
|
BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results
|
|
Mar 26
|
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
|
|
Mar 19
|
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
|
|
Mar 7
|
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
|
Dec 23
|
Co-Founder of BioAtla Jay Short Buys 2.3% More Shares
|
|
Dec 20
|
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 6
|
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023
|
|
Dec 5
|
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
|
|
Nov 30
|
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
|
|
Nov 28
|
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
|
|
Nov 12
|
BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
|